Skip to main content
Signal8

BriaCell Therapeutics Corp. (BCTX) Form 10-Q — Jun 9, 2026

$BCTXForm 10-QFiled Jun 9, 2026, 4:06 PM ET0001493152-26-027928Original filing

BriaCell Therapeutics reported a net loss of $22.6 million for the nine months ended April 30, 2026, driven by $18.7 million in R&D expenses as it advances its pivotal Phase 3 breast cancer trial. The company holds $22.8 million in total liquidity (cash and short-term investments) but disclosed substantial doubt about its ability to continue as a going concern, noting dependence on future financing. Despite the financial headwinds, BriaCell highlighted significant clinical momentum, including a feature in Nature Medicine’s Year in Review and positive Phase 2 survival data showing patients living 18-47 months post-enrollment.

Key figures

Total Debt
71854
Total Assets
27071310
Cash Position
6880221
Shares Outstanding
7250487
Total Liquidity
22804425
Jan2026 Offering Price
5.59
Rd Expenses Nine Months
18704005
Short Term Investments
15924204
Jan2026 Offering Shares
5366726
June2026 Offering Price
3.25
June2026 Offering Shares
1449300
Briapro Ownership Percent
78
Jan2026 Offering Proceeds
30000000
June2026 Offering Proceeds
4700000
Bc Therapeutics Ownership Percent
69.04

Price after filing

1 day: -6.2%7 days: -7.8%30 days: +20.5%

Close on the filing date to close N calendar days later (from $3.07). Historical, not a forecast.

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.